Chris Boshoff: The U.S. FDA granted full approval for our therapy developed with our partner Genmab
Chris Boshoff shared a post on LinkedIn:
“Today, the U.S. FDA granted full approval for our therapy for the treatment of recurrent or metastatic Cervical Cancer, developed with our partner Genmab. Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease. This approval reinforces the important role of our medicine for these patients, and represents a significant achievement for this patient community who have long faced limited options.”
Read further.
Source: Chris Boshoff/LinkedIn
Chris is Chief Oncology Officer and Executive Vice President for Pfizer. He leads an end-to-end business organization called the Pfizer Oncology Division, which includes drug discovery, early and late phase clinical development, and commercialization of the company’s Oncology portfolio.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023